Irisin prevents disuse-induced osteocyte apoptosis.
Previous results showed that intermittently administered Irisin improves bone mass in normal mice and prevents the development of disuse-induced osteoporosis and muscular atrophy in hind-limb suspended mice, a murine model able to mimic the absence of mechanical loading. A recent study showed that Irisin increases survival of osteocytes acting through integrin αV/β5 receptors. To better understand the action of Irisin on these cells, we investigated the downstream signaling cascades in osteocyte-like cells (MLO-Y4) treated with recombinant Irisin (rec-Irisin) in vitro and we analyzed survival of osteocytes and caspase activation in cortical bone of osteoporotic mice treated with rec-Irisin in vivo. Our results revealed that rec-Irisin activated the MAP kinases Erk1-2 and increased the expression of the transcription factor Atf4 (2.5-fold, p<0.05) through an Erk-dependent pathway in osteocytes. Some key genes expressed by MLO-Y4 cells were modulated by long term Irisin treatment, either continuously administered or given with intermittent short pulses. Interestingly, Sost mRNA was severely downregulated only upon intermittent Irisin administration (10-fold, p<0.001). Furthermore, rec-Irisin upregulated Tfam mRNA (4-fold, p<0.05) and Bcl2/Bax ratio (2-fold, p<0.05) in MLO-Y4 cells. By detecting Caspase-9 and Caspase-3, we also found that rec-Irisin inhibited apoptosis induced by hydrogen peroxide and dexamethasone, respectively. In cortical bone of unloading C57BL6 mice, Irisin prevented disuse-induced reduction of viable osteocytes (+30% Vs unload-veh, p<0.05) and increase of empty lacunae (+110% Vs unload-veh, p<0.05), as well as Caspase-9 (3-fold, p<0.05) and Caspase-3 (2-fold, p<0.05) activations. Our findings revealed underlying mechanisms of Irisin action on osteocytes, which increases their functions and exerts anti-apoptotic effects, confirming that mechanosensor cells of bone are sensitive to the exercise-mimetic myokine Irisin. This article is protected by copyright. All rights reserved.